Skip to main content
Top
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

The changes of Th17 cells and the related cytokines in the progression of human colorectal cancers

Authors: Jiansheng Wang, Kaiyu Xu, Jing Wu, Chenghua Luo, Yuchen Li, Xuebin Wu, Hong Gao, Guosheng Feng, Bao-Zhu Yuan

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

The role of Th17 cells in colorectal tumorigenesis and development still remains unclear, despite the fact that it has been established in the pathogenesis of autoimmune diseases.

Methods

We first analyzed Th17 cells and Treg cells using flow cytometry in the circulation of colorectal adenoma (CRA) and colorectal carcinoma (CRC) patients and healthy controls, and the frequency of Th17 cells in peripheral blood mononuclear cells (PBMCs) stimulated by anti-CD3 plus anti-CD28 and treated by IL-1β, IL-6, and TGF-β in different concentrations. We then detected cytokines IL-1β, IL-6, IL-17A, IL-21, IL-23 or TGF-β by ELISA in sera and supernatants from both normal and tumor tissues cultured ex vivo.

Results

It was found that the percentage of Th17 and Treg cells increased in the circulation of both CRA and CRC patients; the increase of Th17 cells in the circulation occurred in early stages, whereas the increase of Treg cells in the circulation and the increase of Th17 cells in tumor tissues occurred in advanced stages. The subsequent cytokine profiling showed that, along CRC progression, IL-1β, IL-17A and IL-23 underwent a similar change, while IL-6 in CRC exhibited an opposite change, with Th17 cells. In addition, high levels of TGF-β and IL-17A were detected in tumor tissues rather than in normal mucosa. The in vitro experiment further demonstrated that IL-1β, IL-6 or TGF-β modulated Th17 cell expansion in PBMC.

Conclusions

Our study reveals a unique change of Th17 cells, which is regulated possibly by IL-1β, IL-6 and TGF-β in the progression of CRC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Center MM, Jemal A, Ward E: International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009, 18: 1688-1694. 10.1158/1055-9965.EPI-09-0090.CrossRefPubMed Center MM, Jemal A, Ward E: International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009, 18: 1688-1694. 10.1158/1055-9965.EPI-09-0090.CrossRefPubMed
2.
go back to reference Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, Byeon JS, Yeoh KG, Goh KL, Sollano J, Rerknimitr R, Matsuda T, Wu KC, Ng S, Leung SY, Makharia G, Chong VH, Ho KY, Brooks D, Lieberman DA, Chan FK: Asia Pacific Working Group on Colorectal Cancer: Asia Pacific consensus recommendations for colorectal cancer screening. Gut. 2008, 57: 1166-1176. 10.1136/gut.2007.146316.CrossRefPubMed Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, Byeon JS, Yeoh KG, Goh KL, Sollano J, Rerknimitr R, Matsuda T, Wu KC, Ng S, Leung SY, Makharia G, Chong VH, Ho KY, Brooks D, Lieberman DA, Chan FK: Asia Pacific Working Group on Colorectal Cancer: Asia Pacific consensus recommendations for colorectal cancer screening. Gut. 2008, 57: 1166-1176. 10.1136/gut.2007.146316.CrossRefPubMed
3.
go back to reference Leslie A, Carey FA, Pratt NR, Steele RJ: The colorectal adenoma-carcinoma sequence. Br J Surg. 2002, 89: 845-860. 10.1046/j.1365-2168.2002.02120.x.CrossRefPubMed Leslie A, Carey FA, Pratt NR, Steele RJ: The colorectal adenoma-carcinoma sequence. Br J Surg. 2002, 89: 845-860. 10.1046/j.1365-2168.2002.02120.x.CrossRefPubMed
4.
go back to reference Contasta I, Pellegrini P, Berghella AM, Del Beato T, Adorno D: Colon cancer and gene alterations: their immunological implications and suggestions for prognostic indices and improvements in biotherapy. Cancer Biother Radiopharm. 2006, 21: 488-505. 10.1089/cbr.2006.21.488.CrossRefPubMed Contasta I, Pellegrini P, Berghella AM, Del Beato T, Adorno D: Colon cancer and gene alterations: their immunological implications and suggestions for prognostic indices and improvements in biotherapy. Cancer Biother Radiopharm. 2006, 21: 488-505. 10.1089/cbr.2006.21.488.CrossRefPubMed
5.
go back to reference Cui G, Goll R, Olsen T, Steigen SE, Husebekk A, Vonen B, Florholmen J: Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol Immunother. 2007, 56: 985-995. 10.1007/s00262-006-0259-y.CrossRefPubMed Cui G, Goll R, Olsen T, Steigen SE, Husebekk A, Vonen B, Florholmen J: Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol Immunother. 2007, 56: 985-995. 10.1007/s00262-006-0259-y.CrossRefPubMed
6.
go back to reference Berghella AM, Contasta I, Pellegrini P, Del Beato T, Adorno D: Are immunological mechanisms involved in colon cancer and are they possible markers for biotherapy improvement?. Cancer Biother Radiopharm. 2006, 21: 468-487. 10.1089/cbr.2006.21.468.CrossRefPubMed Berghella AM, Contasta I, Pellegrini P, Del Beato T, Adorno D: Are immunological mechanisms involved in colon cancer and are they possible markers for biotherapy improvement?. Cancer Biother Radiopharm. 2006, 21: 468-487. 10.1089/cbr.2006.21.468.CrossRefPubMed
7.
go back to reference Pellegrini P, Berghella AM, Contasta I, Del Beato T, Adorno D: The study of a patient's immune system may prove to be a useful noninvasive tool for stage classification in colon cancer. Cancer Biother Radiopharm. 2006, 21: 443-467. 10.1089/cbr.2006.21.443.CrossRefPubMed Pellegrini P, Berghella AM, Contasta I, Del Beato T, Adorno D: The study of a patient's immune system may prove to be a useful noninvasive tool for stage classification in colon cancer. Cancer Biother Radiopharm. 2006, 21: 443-467. 10.1089/cbr.2006.21.443.CrossRefPubMed
8.
go back to reference Cui G, Florholmen J: Polarization of cytokine profile from Th1 into Th2 along colorectal adenoma-carcinoma sequence: implications for the biotherapeutic target?. Inflamm Allergy Drug Targets. 2008, 7: 94-97. 10.2174/187152808785107589.CrossRefPubMed Cui G, Florholmen J: Polarization of cytokine profile from Th1 into Th2 along colorectal adenoma-carcinoma sequence: implications for the biotherapeutic target?. Inflamm Allergy Drug Targets. 2008, 7: 94-97. 10.2174/187152808785107589.CrossRefPubMed
9.
go back to reference Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964. 10.1126/science.1129139.CrossRefPubMed Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964. 10.1126/science.1129139.CrossRefPubMed
10.
go back to reference Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005, 353: 2654-2666. 10.1056/NEJMoa051424.CrossRefPubMed Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005, 353: 2654-2666. 10.1056/NEJMoa051424.CrossRefPubMed
11.
go back to reference Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS: Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009, 15: 6412-6420. 10.1158/1078-0432.CCR-09-1438.CrossRefPubMedPubMedCentral Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS: Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009, 15: 6412-6420. 10.1158/1078-0432.CCR-09-1438.CrossRefPubMedPubMedCentral
12.
go back to reference Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6: 295-307. 10.1038/nri1806.CrossRefPubMed Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6: 295-307. 10.1038/nri1806.CrossRefPubMed
13.
go back to reference Gallimore AM, Simon AK: Positive and negative influences of regulatory T cells on tumour immunity. Oncogene. 2008, 27: 5886-5893. 10.1038/onc.2008.269.CrossRefPubMed Gallimore AM, Simon AK: Positive and negative influences of regulatory T cells on tumour immunity. Oncogene. 2008, 27: 5886-5893. 10.1038/onc.2008.269.CrossRefPubMed
14.
go back to reference Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, FazekasdeStGroth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006, 203: 1701-1711. 10.1084/jem.20060772.CrossRefPubMedPubMedCentral Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, FazekasdeStGroth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006, 203: 1701-1711. 10.1084/jem.20060772.CrossRefPubMedPubMedCentral
15.
go back to reference Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, Xue J, Zhang FM, Ge HL, Xu D: CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol. 2009, 131: 109-118. 10.1016/j.clim.2008.11.010.CrossRefPubMed Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, Xue J, Zhang FM, Ge HL, Xu D: CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol. 2009, 131: 109-118. 10.1016/j.clim.2008.11.010.CrossRefPubMed
17.
go back to reference Miossec P, Korn T, Kuchroo VK: Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009, 361: 888-898. 10.1056/NEJMra0707449.CrossRefPubMed Miossec P, Korn T, Kuchroo VK: Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009, 361: 888-898. 10.1056/NEJMra0707449.CrossRefPubMed
18.
go back to reference Leung S, Liu X, Fang L, Chen X, Guo T, Zhang J: The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol Immunol. 2010, 7: 182-189. 10.1038/cmi.2010.22.CrossRefPubMedPubMedCentral Leung S, Liu X, Fang L, Chen X, Guo T, Zhang J: The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol Immunol. 2010, 7: 182-189. 10.1038/cmi.2010.22.CrossRefPubMedPubMedCentral
19.
go back to reference Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006, 441: 235-238. 10.1038/nature04753.CrossRefPubMed Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006, 441: 235-238. 10.1038/nature04753.CrossRefPubMed
20.
go back to reference Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR: TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008, 453: 236-240. 10.1038/nature06878.CrossRefPubMedPubMedCentral Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR: TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008, 453: 236-240. 10.1038/nature06878.CrossRefPubMedPubMedCentral
22.
go back to reference Mills KH: Induction, function and regulation of IL-17-producing T cells. Eur J Immunol. 2008, 38: 2636-2649. 10.1002/eji.200838535.CrossRefPubMed Mills KH: Induction, function and regulation of IL-17-producing T cells. Eur J Immunol. 2008, 38: 2636-2649. 10.1002/eji.200838535.CrossRefPubMed
23.
go back to reference Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler DA: IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 2008, 454: 350-352. 10.1038/nature07021.CrossRefPubMedPubMedCentral Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler DA: IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 2008, 454: 350-352. 10.1038/nature07021.CrossRefPubMedPubMedCentral
24.
go back to reference Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupé P, Barillot E, Soumelis V: A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008, 9: 650-657.CrossRefPubMed Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupé P, Barillot E, Soumelis V: A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008, 9: 650-657.CrossRefPubMed
25.
go back to reference Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F: Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007, 8: 942-949.CrossRefPubMed Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F: Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007, 8: 942-949.CrossRefPubMed
26.
go back to reference Manel N, Unutmaz D, Littman DR: The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008, 9: 641-649. 10.1038/ni.1610.CrossRefPubMedPubMedCentral Manel N, Unutmaz D, Littman DR: The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008, 9: 641-649. 10.1038/ni.1610.CrossRefPubMedPubMedCentral
27.
go back to reference Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, Poindron P, Duclos B: Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut. 1996, 39: 684-689. 10.1136/gut.39.5.684.CrossRefPubMedPubMedCentral Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, Poindron P, Duclos B: Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut. 1996, 39: 684-689. 10.1136/gut.39.5.684.CrossRefPubMedPubMedCentral
28.
go back to reference Shanahan F, Brogan M, Targan S: Human mucosal cytotoxic effector cells. Gastroenterology. 1987, 92: 1951-1957.CrossRefPubMed Shanahan F, Brogan M, Targan S: Human mucosal cytotoxic effector cells. Gastroenterology. 1987, 92: 1951-1957.CrossRefPubMed
29.
go back to reference Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W: Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007, 178: 6730-6733.CrossRefPubMed Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W: Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007, 178: 6730-6733.CrossRefPubMed
30.
go back to reference Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G: Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol. 2010, 184: 1630-1641. 10.4049/jimmunol.0902813.CrossRefPubMed Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G: Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol. 2010, 184: 1630-1641. 10.4049/jimmunol.0902813.CrossRefPubMed
31.
go back to reference Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, Xue X, Wei G, Liu X, Fang G: The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun. 2008, 374: 533-537. 10.1016/j.bbrc.2008.07.060.CrossRefPubMed Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, Xue X, Wei G, Liu X, Fang G: The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun. 2008, 374: 533-537. 10.1016/j.bbrc.2008.07.060.CrossRefPubMed
32.
go back to reference Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF: Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A. 2008, 105: 15505-15510. 10.1073/pnas.0710686105.CrossRefPubMedPubMedCentral Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF: Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A. 2008, 105: 15505-15510. 10.1073/pnas.0710686105.CrossRefPubMedPubMedCentral
33.
go back to reference Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G: Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009, 114: 1141-1149. 10.1182/blood-2009-03-208249.CrossRefPubMedPubMedCentral Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G: Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009, 114: 1141-1149. 10.1182/blood-2009-03-208249.CrossRefPubMedPubMedCentral
34.
go back to reference Rovedatti L, Kudo T, Biancheri P, Sarra M, Knowles CH, Rampton DS, Corazza GR, Monteleone G, Di Sabatino A, Macdonald TT: Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009, 58: 1629-1636. 10.1136/gut.2009.182170.CrossRefPubMed Rovedatti L, Kudo T, Biancheri P, Sarra M, Knowles CH, Rampton DS, Corazza GR, Monteleone G, Di Sabatino A, Macdonald TT: Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009, 58: 1629-1636. 10.1136/gut.2009.182170.CrossRefPubMed
35.
go back to reference Ye J, Su X, Hsueh EC, Zhang Y, Koenig JM, Hoft DF, Peng G: Human tumor-infiltrating Th17 cells have the capacity to differentiate into IFN-γ + and FOXP3+ T cells with potent suppressive function. Eur J Immunol. 2011, 41: 936-951. 10.1002/eji.201040682.CrossRefPubMed Ye J, Su X, Hsueh EC, Zhang Y, Koenig JM, Hoft DF, Peng G: Human tumor-infiltrating Th17 cells have the capacity to differentiate into IFN-γ + and FOXP3+ T cells with potent suppressive function. Eur J Immunol. 2011, 41: 936-951. 10.1002/eji.201040682.CrossRefPubMed
36.
go back to reference Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F: Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood. 2011, 117: 6532-6541. 10.1182/blood-2010-11-317321.CrossRefPubMed Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F: Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood. 2011, 117: 6532-6541. 10.1182/blood-2010-11-317321.CrossRefPubMed
Metadata
Title
The changes of Th17 cells and the related cytokines in the progression of human colorectal cancers
Authors
Jiansheng Wang
Kaiyu Xu
Jing Wu
Chenghua Luo
Yuchen Li
Xuebin Wu
Hong Gao
Guosheng Feng
Bao-Zhu Yuan
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-418

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine